Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP: PHRRF )

0.1530 UNCHANGED
Streaming Delayed Price Updated: 3:56 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Pharmather Hldgs Ltd

< Previous 1 2 Next >
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
Depression Relief: Possible Therapy Boost With DMT & SSRIs Small Pharma Clinical Results New findings on safety, tolerability and efficacy from a clinical study assessing the interaction of... 
Via Benzinga
PharmaTher Is 'One Step Closer To Being A Ketamine Leader' Due To FDA Acceptance
The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product. 
Via Benzinga
Exposures Product Safety
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035. 
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application
Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t 
Via Benzinga
Exposures Product Safety
Psyched: Germany Ships LSD Prodrugs Via DHL, Minneapolis Decriminalizes, Wiz Khalifa's Magic Pitch & More
Minneapolis Mayor Deprioritizes Psychedelics: 'We Should Be In The Business Of Helping People' Minneapolis Mayor Jacob Frey recently signed an executive order effectively deprioritizing criminal... 
Via Benzinga
PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward The Clinical Stage
PharmaTher Holdings (OTCQB: PHRRF) and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes. 
Via Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
World's Largest Psychedelics Conference Boasts 12K Attendees 
Via Benzinga
BetterLife Fast Tracks Its US Patent For Non-Hallucinogenic Compound And Other LSD Derivatives
Psychedelics biotech BetterLife Pharma Inc. (OTCQB: BETRF) is fast-tracking its U.S. 
Via Benzinga
Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets
Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic... 
Via Benzinga
PharmaTher's Novel Ketamine Heads For The US Market With New Collaboration Agreement
Psychedelics biotech PharmaTher Holdings (OTCQB: PHRRF) has entered into a collaborative partnership with pharma marketing company Vitruvias Therapeutics for the commercialization of its proprietary... 
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
Parkinson's Patients May Benefit From Ketamine, PharmaTher Applies For FDA Fast Track
Specialty pharmaceutical company PharmaTher Holdings (OTCQB: PHRRF) has submitted a Fast Track Application to the Food and D 
Via Benzinga
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... 
Via Benzinga
MDMA Transdermal Patch Moves Toward First-In-Human Trials: Latest Development Update
Specialty drug delivery technology biopharma company Revive Therapeutics Ltd. (OTCQB: RVVTF) is undertaking research and development activities for its proprietary transdermal microneedle patch to... 
Via Benzinga
Ketamine Company Advances Parkinson's Treatment Through Final Stages Toward FDA Approval
PharmaTher Holdings Ltd. 
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
Via Benzinga
Development Of DMT Transdermal Patch With Eye Disease Treatment In Mind
Specialty R&D psychedelics company PharmaDrug Inc. (OTCQB: LMLLF) has inked a research collaboration agreement with PharmaTher Holdings Ltd. (OTCMKTS: PHRRF) to evaluate the delivery of DMT through... 
Via Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
PharmaTher Seeks Regulatory Approval Of New Ketamine Delivery System For Anesthesia And Sedation
Specialty ketamine company PharmaTher Holdings Ltd. 
Via Benzinga
Psyched: Australia Legalizes Psychedelics Therapy, BC's Decrim, State Bills, Millions For Trials & Clinics
Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically... 
Via Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve 
Via Benzinga
PharmaTher Holdings Nabs New Orphan Drug Status, Discusses Further Fast-Track, Partners For MDMA Patch
Ketamine products manufacturer PharmaTher Holdings Ltd. (OTCQB: PHRRF) had lots happening this past week. Here are the company's top three news items. 
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Search Is On For Psychedelic Patents & FDA Designations, 3 Companies Share News
Drug discovery company Mindset Pharma (OTCQB: MSSTF) has been greenlighted by the US Patent and Trademark Office (USPTO) on its application “Psilocin Derivatives As Serotonergic Psychedelic Agents for... 
Via Benzinga
Psychedelics Market Could Reach $12B By 2029, Says New Report
A new analysis of the global market for psychedelics performed by Brandessence Market Research shows an expected growth from 2022’s $4.87 billion to an annual valuation of nearly $12 billion before... 
Via Benzinga
2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products
Two psychedelics companies have shared their updates and key milestones to be reached this 2023. 
Via Benzinga
FDA OKs Ketamine For Treating Organ Transplant Injuries With 'Orphan Drug' Status
The U.S. Food and Drug Administration (FDA) has granted PharmaTher Holdings Ltd. (OTCQB: PHRRF) an Orphan Drug designation for ketamine in the prevention of injury from organ transplantation. 
Via Benzinga
Ketamine Could Soon Be A Treatment Option For This Rare Genetic Neurological Disorder
Specialty biopharma company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has entered into an evaluation and exclusive option agreement with Case Western Reserve University (CWRU) 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.